Want to track FGEN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program
FibroGen Inc. FGEN saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in pancreatic cancer patients.
Benzinga | 1 year ago
FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts
FibroGen (NASDAQ: FGEN ) layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. FibroGen says that it is going into a cost-saving mode that will result in layoffs for 75% of its U.S. employees.
Investorplace | 1 year ago
Why Is FibroGen (FGEN) Stock Down 44% Today?
FibroGen (NASDAQ: FGEN ) stock is falling hard on Wednesday after the biopharmaceutical company reported results from failed clinical trials. The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab.
Investorplace | 1 year ago
